Clinical Trials Logo

Blepharospasm, Benign Essential clinical trials

View clinical trials related to Blepharospasm, Benign Essential.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04423341 Completed - Blepharospasm Clinical Trials

Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm

Start date: May 20, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The planned study is a prospective analysis of non-psychoactive Cannabidiol (without THC) as an adjunctive therapy for blepharospasm in a masked double cross-over study. This prospective study is a follow-up to a retrospective study completed by the researchers using over-the-counter, self purchased CBD. This study will use FDA approved Cannabidiol medication, Epidiolex, directly from GW pharmaceuticals, rather than self-purchased CBD from the internet. Patients will undergo videorecording with a high resolution videocamera system at days 0, 45, 90, 135, and 180 using a novel blink analysis to gather objective data measurements of changes induced by CBD in Blepharospasm patients. This study will attempt to codify the data and quantify if adjunctive CBD therapy improves those areas compared to botulinum injection alone.

NCT ID: NCT03903341 Completed - Clinical trials for Blepharospasm, Benign Essential

The Role of the Upper Colliculus in the Idiopathic Blepharospasm

COLL-BSP
Start date: November 20, 2019
Phase: N/A
Study type: Interventional

This pilot study aims at investigating the role of superior colliculus in patients with idiopathic blepharospasm (BSP) de novo, compared to healthy subjects.